ACEA BIO

company

About

ACEA Biosciences is a biotechnology company that develops and commercializes high-performance microelectronic systems for cell-based assays.

  • 251 - 500

Details

Last Funding Type
Series E
Last Funding Money Raised
$6M
Industries
Biotechnology,Clinical Trials,Real Time,Sensor
Founded date
Jan 1, 2002
Number Of Employee
251 - 500
Operating Status
Active

ACEA Biosciences is a biotechnology company founded in 2002 and headquartered in San Diego, California. ACEA is a pioneer in the development and commercialization of high-performance microelectronic systems for cell-based assays. ACEA has a world-class manufacturing operation centered in Hangzhou, Zhejiang Province, China.

The Life Technology Business Unit developed ACEA’s proprietary real-time, label-free cell-based assay technology and launched the first product in 2004. The technology has been marketed globally under the xCELLigence brand. There are over 800 customers worldwide, and over 350 peer-reviewed publications using the xCELLigence technology.

The newly launched iCELLigence instrument with wireless connectivity makes this innovative technology affordable to all users. In addition to the Life Technology Business Unit, ACEA also has a Therapeutics Business Unit which was launched in 2005.

ACEA Therapeutics is focused on oncology drug discovery and development, leveraging the platform biosensor technology and proprietary small molecule library (> 1 million compounds) to bring novel therapeutics into the clinic. ACEA currently has one program in phase II clinical trials in China and numerous early clinical and preclinical leads. With its international reach, ACEA Biosciences continues to work closely with scientists throughout the world to bring innovation to the R&D and health care industries.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$36M
ACEA BIO has raised a total of $36M in funding over 2 rounds. Their latest funding was raised on Apr 1, 2016 from a Series E round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 1, 2016 Series E $6M 1 Detail
Nov 9, 2015 Series Unknown $30M 1 Lilly Asia Ventures Detail

Investors

Number of Lead Investors
Number of Investors
1
1
ACEA BIO is funded by 1 investors. Lilly Asia Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Lilly Asia Ventures Series E